Tilman SA
212.0 FTEThe score of Tilman shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +17 % Equity +3 % Total assets +6 % Headcount (avg FTE) +13 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Tilman's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €58.2m | ||||
| Net result | −€1.11m | ||||
| Equity | €12.8m | ||||
| Cash | 511,337 € | ||||
| EBITDA | €6.45m | ||||
| Total assets | €43.2m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 Jul 2026
- Year ended 31 Dec 2024filed on 30 Jul 2025
- Year ended 31 Dec 2023filed on 20 Jun 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 20 Jul 2022
Tilman's financial analysis
- Solvency29.5%sector median: 34.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Tilman
Tilman's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0458.493.759
- VAT number
- BE0458493759
- Peppol
- Registered · 0208:0458493759 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 15 Jul 1996
- Registered office
- 5377 Somme-Leuze
- Size
- Medium · 212.0 FTE
- Latest accounts
- 2025 · filed on 29 Jul 2026
- Activity
- Manufacture of medicaments (NACE 21201)
Tilman (SA) has been based in Somme-Leuze since 1996, active in: manufacture of medicaments. For 2025, it reports revenue of €58.2m, a net loss of €1.11m and equity of €12.8m. With 212.0 full-time equivalents, it is a medium-sized enterprise by headcount. Its solvency stands at 29.5%, below the median of its sector (34.4%).
Companies similar to Tilman
Companies in the same business, of comparable size and area, outside its group.
- BePharBel Manufacturing Manufacture of basic pharmaceutical products Courcelles · balance sheet €27.4m
- Ipsen Manufacture of pharmaceutical preparations Brussels · balance sheet €134.4m
- Medgenix Benelux Manufacture of pharmaceutical preparations Wevelgem · balance sheet €39.4m
- Laboratoria Qualiphar Manufacture of pharmaceutical preparations Bornem · balance sheet €50.8m
- Conforma Manufacture of pharmaceutical preparations Destelbergen · balance sheet €16.3m
- Novo Nordisk Production Belgium SA Manufacture of pharmaceutical preparations Brussels · balance sheet €153.5m
- Odyssea Pharma Manufacture of pharmaceutical preparations Grâce-Hollogne · balance sheet €91.0m
- Laboratoires Sterop Manufacture of pharmaceutical preparations Anderlecht · balance sheet €23.9m
Frequently asked questions about Tilman
What is the revenue of Tilman?
According to the 2025 annual accounts filed with the NBB, the revenue of Tilman amounts to 58,228,136 €.
What is the VAT number of Tilman?
In Belgium, the VAT number is the company number prefixed with BE: BE0458493759 for Tilman, if the company is VAT-registered. Its company number (CBE) is 0458.493.759.
Where is the registered office of Tilman?
According to the CBE register, the registered office of Tilman is in 5377 Somme-Leuze.
What is the equity of Tilman?
At the close of the 2025 financial year, the equity of Tilman amounts to 12,770,396 €, a solvency of 29.5% of total assets.
How many people work at Tilman?
212.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Tilman?
The register lists 13 active mandates at Tilman. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Tilman
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →